Spots Global Cancer Trial Database for Fludara (Oral) Phase II Study for Indolent Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Fludara (Oral) Phase II Study for Indolent Lymphoma
Official Title: A Multicenter, Open Study to Assess the Antitumor Effect and Safety of Oral Fludarabine Phosphate (Fludara (SH T 586): 40 mg/m2/Day) Administered in 3 - 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by a Observation Period of 23 Days) in Patients With Indolent Lymphoma
Study ID: NCT00688883
Conditions
Interventions
Study Description
Brief Summary: To assess the antitumor effect and safety of Fludara in patients with indolent lymphoma.
Detailed Description: As of 29 May 2009, the clinical trial sponsor is Genzyme Corporation. NOTE: This study was originally posted by sponsor Schering AG, Germany, which was subsequently renamed to Bayer Schering Pharma AG, Germany.
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Nagoya-shi, Aichi, Japan
, Nagoya-shi, Aichi, Japan
, Kashiwa-shi, Chiba, Japan
, Fukuoka-shi, Fukuoka, Japan
, Fukuoka-shi, Fukuoka, Japan
, Sapporo-shi, Hokkaido, Japan
, Akashi-shi, Hyogo, Japan
, Kagoshima-shi, Kagoshima, Japan
, Isehara-shi, Kanagawa, Japan
, Kyoto-shi, Kyoto, Japan
, Sendai-shi, Miyagi, Japan
, Nagasaki-shi, Nagasaki, Japan
, Okayama-shi, Okayama, Japan
, Moriguchi-shi, Osaka, Japan
, Hamamatsu-shi, Shizuoka, Japan
, Chuo-ku, Tokyo, Japan
, Shinjuku-ku, Tokyo, Japan
Contact Details
Name: Medical Monitor
Affiliation: Genzyme, a Sanofi Company
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
